Recurrent and De Novo Cirrhosis After Liver Transplantation Authors: Abhinav K Rao, Don C Rockey Published: 2026 ABSTRACT ABSTRACTAimsLiver transplantation is often curative for patients with cirrhosis; however, some patients subsequently develop cirrhosis in the transplanted graft, either due to recurrence of the original cause of liver disease or development of a new type of liver disease (de novo). Here, we examined patients who developed recurrent or de novo cirrhosis after undergoing liver transplantation for cirrhosis.MethodsWe examined consecutive adult liver transplant patients who underwent liver transplantation for cirrhosis and were followed between January 1, 1987, and December 31, 2023, at our institution. Patients transplanted for indications other than cirrhosis, including acute liver failure, were excluded. Patients with active hepatitis C virus infection at the time of transplantation were excluded from the primary analysis. Cirrhosis after transplant was defined by histology demonstrating bridging fibrosis or the presence of clinical complications of portal hypertension. In the evaluation of mortality risk, propensity score matching was used to compare liver transplant recipients with and without cirrhosis after liver transplant, and survival was assessed using Kaplan–Meier analysis.ResultsIn total, 937 unique patients were included; 107 (11.4%) developed cirrhosis subsequent to transplantation with a median (interquartile range) time to cirrhosis of 7.8 (8.3) years after transplant. In total, 89 of 107 (83.2%) patients developed the same liver disease that caused cirrhosis initially and led to transplantation. Autoimmune hepatitis (16/55, 29.1%) and primary biliary cholangitis (11/52, 21.2%) most commonly recurred after liver transplantation. Overall, de novo cirrhosis occurred in 18/937 (1.9%) of all patients, accounting for 16.8% (18/107) of patients who developed cirrhosis, most commonly due to chronic rejection (9/18) or metabolic dysfunction‐associated steatohepatitis (4/18). Patients with cirrhosis after transplant had a significantly lower survival rate at 20 years (50.6% vs. 70.7%, hazard ratio: 1.77; 95% confidence interval: 1.09–2.88; log‐rank test; p < 0.05) after liver transplantation compared to those without cirrhosis after transplant.ConclusionCirrhosis after transplant is uncommon, but when it occurs, it is most often due to recurrence of the primary liver disease, with the highest recurrence rates observed in patients with autoimmune hepatitis and primary biliary cholangitis. De novo cirrhosis is most commonly associated with chronic rejection or metabolic dysfunction‐associated steatohepatitis. Patients developing cirrhosis after transplant have reduced long‐term survival.Keywords: death, decompensation, mortality, outcome, rejection Introduction Liver fibrosis results from a response to hepatic injury [1] and ultimately leads to cirrhosis with its associated clinical features. Liver transplantation remains the primary treatment for patients with fibrosis who develop cirrhosis [2]. An important concern in the field of transplantation is the development of fibrosis and cirrhosis after liver transplantation [3]. The causes of post‐transplant fibrosis and cirrhosis, along with the associated morbidity and mortality, remain poorly understood. It is possible that the pathophysiology of pre‐ and post‐transplant cirrhosis is similar, perhaps involving a systemic mediator [4, 5, 6, 7]; in this scenario, the etiology of recurrent post‐transplant cirrhosis is likely the same as that of the primary liver disease (i.e., recurrent cirrhosis). However, post‐transplant cirrhosis may also arise from a different etiology than the pre‐transplant disease (de novo cirrhosis) [4, 5, 8]. Here, we hypothesized that patients who develop cirrhosis after liver transplantation may have either (1) recurrence of their primary liver disease or (2) cirrhosis due to a different etiology. Therefore, we examined this patient population, specifically focusing on both recurrent and de novo post‐transplant cirrhosis. We further assessed the outcomes in these patients. Methods Study Population and Design We examined consecutive liver transplant patients who underwent liver transplantation for cirrhosis and were followed between January 1, 1987, and December 31, 2023, at the Medical University of South Carolina (MUSC). Cirrhosis patients were identified using the MUSC Clinical Data Warehouse (CDW) based on ICD‐9 and ICD‐10 codes as described [9]. The diagnoses of cirrhosis (both pre‐ and post‐transplant) were validated through a review of the medical record. Complete liver transplant data were abstracted. The study included patients older than 18 years. Patients with non‐cirrhosis indications, such as acute liver failure, malignancies, familial metabolic diseases, benign tumors, or biliary atresia were excluded. Given the confounding effect of active hepatitis C virus (HCV) infection on fibrogenesis, we excluded patients with active HCV from the primary analysis (this subgroup was examined separately in a sensitivity analysis). The study was approved by the MUSC Institutional Review Board and adhered to all guidelines for good clinical practice. Data Abstraction and Definitions We evaluated the development of cirrhosis after liver transplantation in patients with cirrhosis pre‐transplant. The diagnosis of cirrhosis was made based on liver histology demonstrating advanced fibrosis (bridging fibrosis) and/or clinical complications of portal hypertension. Patients with F4 fibrosis on histology were classified as having cirrhosis, while patients with F1 to F3 fibrosis were classified as having cirrhosis only if complications of portal hypertension were present [10]. For patients without liver biopsy results, the diagnosis of cirrhosis was made based on imaging findings consistent with cirrhosis, along with the presence of complications of elevated portal pressure including ascites, spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS), varices, or hepatic encephalopathy (HE). Patients with cirrhosis after transplantation were classified as having either recurrent cirrhosis, defined as post‐transplant cirrhosis caused by the same disease responsible for the initial pre‐transplant cirrhosis, or de novo cirrhosis, defined as post‐transplant cirrhosis etiologically different from the cause of pre‐transplant liver disease. Recurrent cirrhosis was determined by histology when available or, in the small number of patients without histologic confirmation, by comprehensive clinical assessment demonstrating features consistent with recurrence of the primary disease. For example, in patients transplanted for alcohol‐associated cirrhosis, documented post‐transplant alcohol relapse in the setting of subsequent cirrhosis supported a diagnosis of recurrent alcohol‐associated cirrhosis. De novo cirrhosis was diagnosed only after recurrent disease was excluded; all patients classified as having de novo cirrhosis had histology excluding recurrence of the primary disease, and subsequent histologic findings were closely examined to determine the etiology of de novo cirrhosis. The study's primary endpoint was mortality, and the secondary endpoint was etiology of post‐transplant cirrhosis (both recurrent and de novo). Statistical Analysis To calculate mortality from cirrhosis after transplant, we used propensity matching (caliper width of 0.1, nearest‐neighbor matching, C statistic 0.6) to compare liver transplant recipients between two groups—(1) those with recurrent post‐transplant cirrhosis and (2) those without post‐transplant cirrhosis (control group). Age at transplant and sex were used to match patients in the post‐transplant cirrhosis and control groups (both standardized mean differences [SMDs] after matching: < 0.1). Because time zero was defined as the date of liver transplantation, when all recipients effectively had a newly transplanted liver, measures of liver disease severity (e.g., Model for End‐Stage Liver Disease [MELD] score) were not included in the propensity score model. Patients with more than one liver transplant were excluded from the propensity score matching analysis. Kolmogorov–Smirnov tests were performed to examine variable distributions. Continuous variables were presented as means with standard deviations (SDs) for normally distributed data, while non‐normally distributed variables were shown as medians with interquartile ranges (IQRs). Discrete variables were expressed as proportions. Chi‐square tests or Fisher's exact tests were performed for discrete variables as appropriate. Continuous variables were analyzed using t‐tests or Mann–Whitney U tests based on normality of distributions. Survival analysis was performed using the Kaplan–Meier method. Patients with multiple liver transplants were excluded from the survival analysis. Patients were censored at death or at the end of the study period. Statistical analyses were conducted using R (version 4.4.1, Beagle Scouts; R Core Team) and Python (version 3.12.4; Python Software Foundation). p‐Values less than 0.05 were considered to be statistically significant. Sensitivity Analysis Given the known recurrence of HCV‐mediated liver disease in patients transplanted with active HCV, and the subsequent availability of direct‑acting antiviral agent (DAA) therapy—which offers a high HCV cure rate [7, 11, 12], we specifically examined and compared patients who developed post‐transplant HCV cirrhosis versus those with non‐HCV cirrhosis. We specifically evaluated the recurrence of primary liver disease in both subgroups (HCV vs. non‐HCV post‐transplant cirrhosis). We also performed stratified analyses with respect to the onset of DAA therapy; given that US Food and Drug Administration (FDA) approval for DAA was in 2014, we defined the post‐DAA period as after 2014, and the pre‐DAA period as up to the end of 2014. For this analysis, patients with post‐transplant HCV cirrhosis were stratified according to whether cirrhosis developed before or after 2014. “Active” HCV was defined as the presence of HCV RNA at the time of transplant, while “cured” HCV was defined as the absence of HCV RNA at the time of transplant. Results Clinical Characteristics During the study period, 1537 patients underwent liver transplantation. Of these, 295 patients were transplanted for non‐cirrhotic indications and were excluded. Additionally, 305 patients underwent transplantation for cirrhosis due to HCV and had active HCV at the time of transplantation—these patients were excluded from the primary analysis. Of the remaining 937 patients who underwent liver transplantation for cirrhosis, 107 (11.4%) patients developed cirrhosis after transplantation (mean duration of follow‐up was 18.8 ± 7.4 years) (Figures 1 and 2). Among these 107 patients, 90 (84.1%) had clinical features of portal hypertension. Liver histology was available in 93/107 (86.9%) patients: 86 had F4 fibrosis, and 7 had F2–F3 fibrosis with clinical features of portal hypertension. Of those with F4 fibrosis, 83/86 (96.5%) also had portal hypertension‐related complications. In the 14 patients without liver histology, all had imaging findings consistent with cirrhosis and clinical features of portal hypertension. Patients with post‐transplant cirrhosis were predominantly elderly White males, with a median Model for End‐Stage Liver Disease incorporating sodium (MELD‐Na) of 17 at the time of cirrhosis diagnosis (IQR: 12) (Table 1). Patient disposition flowchart of patients with cirrhosis after liver transplantation in this retrospective study. ALF, acute liver failure; HCV, hepatitis C virus. Kaplan–Meier cumulative incidence curve of post‑transplant cirrhosis in 937 patients who underwent liver transplantation for cirrhosis (excluding active HCV). HCV, hepatitis C virus. Table 1Demographic and clinical characteristics of patients at diagnosis of post‐transplant cirrhosis (N = 107).CharacteristicValueFemale, n (%)47 (43.9)Age at post‐transplant cirrhosis diagnosis (years), median (IQR)60 (19)Age at 1st transplant (years), median (IQR)47 (20)White, n (%)75 (70.1)Black, n (%)26 (24.3)Other, n (%)6 (5.6)MELD‐Na, median (IQR)17 (12)Clinical features of portal hypertension, n (%)90 (84.1)Abbreviations: IQR, interquartile range; MELD‐Na, Model for End‐Stage Liver Disease incorporating sodium. Demographic and clinical characteristics of patients at diagnosis of post‐transplant cirrhosis (N = 107). Abbreviations: IQR, interquartile range; MELD‐Na, Model for End‐Stage Liver Disease incorporating sodium. In the 107 patients who developed cirrhosis after transplantation, recurrence of the primary liver disease was the most common cause (89/107, 83.2%), while 18 (16.8%) developed cirrhosis due to another etiology (Tables 2 and 3). The median time to cirrhosis after liver transplantation was 7.8 (IQR: 8.3) years. Chronic rejection was the cause of cirrhosis in 9/107 (8.4%) patients after transplant. Of the 107 patients with post‐transplant cirrhosis, 18 (16.8%) underwent repeat transplantation due to graft failure from cirrhosis in the initial graft. Table 2Incidence of post‐transplant cirrhosis and recurrence of primary disease, stratified by pre‐transplant etiology.Pre‑transplant diagnosisPost‑transplant cirrhosis, n (%)Recurrence of primary disease, n (%)Alpha‐1‐antitrypsin (n = 23)6 (26.1)2 (8.7)Alcohol‐associated (n = 230)22 (9.6)14 (6.1)Autoimmune hepatitis (n = 55)17 (30.9)16 (29.1)Hepatitis B virus (n = 27)5 (18.5)5 (18.5)Metabolic dysfunction‐associated steatohepatitis (n = 474)28 (5.9)24 (5.1)Primary biliary cholangitis (n = 52)12 (23.1)11 (21.2)Primary sclerosing cholangitis (n = 68)11 (16.2)11 (16.2)Other (n = 8)6 (75.0)6 (75.0)Total (N = 937)107 (11.4)89 (9.5) Incidence of post‐transplant cirrhosis and recurrence of primary disease, stratified by pre‐transplant etiology. Table 3Causes of de novo cirrhosis after liver transplantation, by original pre‑transplant disease (n = 18).Primary diagnosisDe novo post‐transplant diagnoses, n Alpha‐1‐antitrypsinAlcohol‐associated: 1; MASH: 2; chronic rejection: 1Alcohol‐associatedMASH: 2; chronic rejection: 5; secondary sclerosing cholangitis: 1Autoimmune hepatitisPrimary biliary cholangitis: 1Metabolic dysfunction‐associated steatohepatitis (MASH)Chronic rejection: 2; alcohol‐associated: 1; secondary sclerosing cholangitis: 1Primary biliary cholangitisChronic rejection: 1 Causes of de novo cirrhosis after liver transplantation, by original pre‑transplant disease (n = 18). Recurrent and De Novo Cirrhosis Etiologies In the 89 patients with recurrent post‐transplant cirrhosis by the same disease as the pre‐transplant etiology, autoimmune hepatitis (16/55, 29.1%) and primary biliary cholangitis (PBC) (11/52, 21.2%) were the most common causes of recurrence (Table 2 and Figure 3). Interestingly, recurrence was relatively infrequent in patients initially transplanted for alcohol‐associated cirrhosis and metabolic dysfunction‐associated steatohepatitis (MASH) (recurrence rates of 14/230 [6.1%] and 24/474 [5.1%], respectively). Of these 22 patients who developed post‐transplant cirrhosis after transplantation for alcohol‐associated liver disease, 14 developed recurrent alcohol‐associated cirrhosis secondary to post‐transplant alcohol recidivism. There were six cases of recurrent cirrhosis due to miscellaneous diseases, including sarcoidosis (n = 2), secondary sclerosing cholangitis (n = 1), cystic fibrosis (n = 1), Budd–Chiari syndrome (n = 1), and secondary biliary cirrhosis (n = 1). Autoimmune hepatitis and alcohol‐associated cirrhosis developed most rapidly after liver transplantation, whereas MASH and PSC developed more slowly (Figure 3). Time to recurrent cirrhosis after liver transplantation, stratified by pre‑transplant etiology (n = 89). (A) Dot plot showing the time from transplant to diagnosis of recurrent cirrhosis for individual patients; horizontal bars represent medians. (B) Cumulative risk of recurrent cirrhosis over time. The curves represent the cumulative incidence for patients with autoimmune hepatitis (16/55), PBC (11/52), PSC (11/68), alcohol‐associated liver disease (14/230), and MASH (24/474). MASH, metabolic dysfunction‑associated steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis. Of the 107 patients with post‐transplant cirrhosis, 18 patients developed cirrhosis due to a new disease (“de novo” cirrhosis) (Table 3). The most common causes in these patients were chronic rejection (9/18, 50.0%) and MASH (4/18, 22.2%). Among patients with de novo cirrhosis, the most common pre‐transplant etiology was alcohol‐associated liver disease (8/18, 44.4%), alpha‐1‐antitrypsin deficiency (4/18, 22.2%), and MASH (4/18, 22.2%). The timing of de novo cirrhosis by etiology varied across groups and is shown in the Supplemental Material (Figure S1). Outcomes To understand the mortality risk associated with post‐transplant cirrhosis, we performed propensity score matching between patients with pre‐transplant cirrhosis who developed post‐transplant cirrhosis (post‐transplant cirrhosis group) and those without post‐transplant cirrhosis (control group) (see Section Methods, 2). After excluding patients with multiple liver transplants (n = 18), we examined 89 matched pairs. The median (IQR) age at transplant was 47 (18), and the majority of patients were Caucasian males in both groups (Table S1). At 20 years after liver transplantation, patients with post‐transplant cirrhosis had a significantly decreased survival probability compared to those without post‐transplant cirrhosis (50.6% vs. 70.7%, hazard ratio [HR]: 1.77; 95% confidence interval [CI]: 1.09–2.88; log‐rank test; p < 0.05; Figure 4). Kaplan–Meier survival analysis comparing patients with and without post‑transplant cirrhosis after liver transplantation (89 propensity‑matched pairs). Patients with post‑transplant cirrhosis had significantly lower long‑term survival. (50.6% vs. 70.7%; hazard ratio [HR]: 1.77; 95% confidence interval [CI]: 1.09–2.88; log‐rank test; p = 0.019). Sensitivity Analysis Given the aggressive nature of recurrent HCV after transplantation, as well as the effectiveness of DAAs in eliminating HCV and the potential effects of HCV elimination on liver fibrosis, we specifically evaluated patients who underwent liver transplantation for HCV cirrhosis. Of the 1242 patients who underwent liver transplantation for cirrhosis, 937 (75.4%) were transplanted for non‐HCV cirrhosis and 305 (24.6%) for HCV cirrhosis (303 of 305 had active HCV at the time of transplant and had not received DAA therapy prior to liver transplantation). Post‐transplant cirrhosis was much more common in patients transplanted for HCV cirrhosis (87/305, 28.5%) than in those transplanted for non‐HCV cirrhosis (107/937, 11.4%). Among patients transplanted for HCV cirrhosis who developed recurrent cirrhosis, nearly all cases (85/87, 97.7%) were due to recurrent HCV. Only two cases were attributed to other causes (one autoimmune hepatitis, one chronic rejection). Of the 305 patients transplanted for HCV, 284 underwent transplant in the pre‐DAA era, with 83 developing recurrent HCV cirrhosis. In the post‐DAA era, only 21 patients were transplanted; all had received DAA therapy. Of these, 19 were treated with DAA after transplant (all of whom were infected in the pre‐DAA era), and 2 received DAA before transplant but developed recurrent HCV cirrhosis after failing treatment. Discussion The current study highlights that cirrhosis after liver transplantation is relatively uncommon, occurring in approximately 11.4% of patients transplanted for cirrhosis (excluding patients with active HCV). Furthermore, in patients who develop post‑transplant cirrhosis, it is typically due to the same disease that caused the initial cirrhosis. Autoimmune hepatitis (29.1%) and PBC (21.2%) had the highest recurrence rates. Although de novo cirrhosis is uncommon, when it occurs, it is most often due to chronic rejection and MASH (Table 3). Finally, patients with post‑transplant cirrhosis had reduced survival compared to those without post‑transplant cirrhosis (50.6% vs. 70.7% survival probabilities at 20 years after transplantation). These findings have important implications for clinical management. First, patients with autoimmune hepatitis appear to be at considerable risk for rapidly progressing recurrent disease, suggesting that disease‑permissive factors present before transplantation may persist and drive post‑transplant liver injury [4, 7]. In patients with HCV, the data imply the important role of viral eradication. In the pre‑DAA era (up to 2014), recurrent HCV cirrhosis developed in 83 of 284 (29.2%) patients transplanted for HCV, whereas in the post‑DAA era (2014 onward), only 21 patients with active HCV at listing underwent transplantation—19 of whom received DAA therapy after transplant and 2 had failed pre‑transplant DAA therapy—and recurrent HCV cirrhosis occurred in only 2 of these 21 (9.5%). This dramatic reduction is consistent with previous reports [11]. Another evolving area is MASH, where patients who continue to exhibit metabolic risk factors after transplantation are at risk for developing recurrent MASH [5] in the graft [4, 5]. Collectively, these observations underscore the need for vigilant monitoring of fibrosis progression after liver transplantation, especially in patients transplanted for autoimmune hepatitis or PBC, who appear to be at highest risk of recurrent cirrhosis. We found that de novo cirrhosis was uncommon after transplantation. When it occurred, it was most often associated with chronic rejection, which we presume was the cause of cirrhosis. The mechanism by which chronic rejection leads to fibrosis after liver transplantation remains unclear but likely involves chronic inflammation, perhaps mediated by T‐cell‐ and antibody‐mediated rejection [13, 14]. In T‐cell‐mediated rejection, activated T cells may induce bile duct atrophy along the portal tracts and vascular changes in the hepatic arteries, including the recruitment of foam cells along the intima and media, resulting in luminal narrowing and arterial thickening (the phenomenon of “foam cell obliterative arteriopathy”) [13, 14, 15]. Whether modifications in immunosuppression regimens can reduce the cirrhosis risk in the setting is unknown and warrants further study. The observed mortality disadvantage among patients with post‐transplant cirrhosis was expected, given the well‑established morbidity and mortality associated with cirrhosis in general [16]. In our cohort, survival curves began to diverge at approximately 6 years after transplantation, which likely reflects the chronic, progressive nature of fibrogenesis and the time required for clinically significant portal hypertension to develop [17]. Patients with cirrhosis after transplantation, similar to patients with cirrhosis before transplant, developed complications of liver decompensation as their cirrhosis progressed, and likely died from common causes of mortality in cirrhosis patients, including variceal bleeding [18, 19, 20], infection [21], SBP [22], HE [23], and HRS [24]. Furthermore, given that patients undergoing liver transplantation require immunosuppression in some form, it could be speculated that infection is a particularly significant cause of mortality in patients with cirrhosis after transplant. Several limitations warrant consideration. First, this was a single‐center study, and the racial and etiological composition of the MUSC cohort may limit generalizability to other transplant populations. Second, the retrospective design spanning four decades (1987–2023) introduces inherent biases, including changes in clinical practice, immunosuppressive regimens, and diagnostic modalities over time; the introduction of DAA therapy for HCV after 2014 was addressed through stratified analyses, but residual era‐related confounding cannot be fully excluded, and competing risks from non‐liver‐related mortality may have influenced the observed recurrence rates. Third, while the majority of post‐transplant cirrhosis cases (86/107, 80.4%) were histologically confirmed as F4 fibrosis, 7 patients were classified as having cirrhosis based on F2–F3 fibrosis with clinical features of portal hypertension, and 14 patients were histologic data unavailable and the diagnosis was based on a combination of clinical features of cirrhosis and supportive radiologic findings; this broader definition may have introduced some misclassification, although a sensitivity analysis restricted to biopsy‐confirmed F4 cases yielded consistent results. Fourth, the propensity score matching used for survival analysis included only age and sex as matching variables; other potential confounders—such as post‐transplant immunosuppressive regimens, metabolic comorbidities (diabetes, hypertension, dyslipidemia), and body mass index—were not incorporated. Although baseline characteristics of the matched cohorts are provided in the Supplemental Materials, residual confounding from unmatched or unmeasured covariates cannot be excluded. Finally, the small number of de novo cirrhosis cases (n = 18) precluded a separate survival comparison between recurrent and de novo etiologies; therefore, the observed survival difference between patients with and without post‐transplant cirrhosis should not be interpreted as reflecting differential prognosis between these two subgroups. Larger multicenter studies with extended follow‐up are needed to validate our findings. In conclusion, cirrhosis after liver transplantation is uncommon. When it develops, it is most commonly due to recurrent cirrhosis, while de novo cirrhosis is uncommon and predominantly associated with chronic rejection. Patients who develop post‐transplant cirrhosis have reduced survival. These findings mandate lifelong surveillance for fibrosis progression in all transplant recipients, and highlight the need for future research into strategies to prevent recurrent and de novo cirrhosis. Author Contributions Abhinav K. Rao contributed to study concept and design, conducted literature review, acquired data, performed statistical analyses, drafted the manuscript, and critically revised the manuscript for significant intellectual content. Don C. Rockey contributed to study concept and design, drafted the manuscript, critically revised the manuscript for significant intellectual content, and provided supervisory efforts. Ethics Statement The retrospective study was approved by the Medical University of South Carolina Institutional Review Board. The Institutional Review Board granted a waiver of written informed consent because this study used de‑identified retrospective electronic health record data and posed minimal risk to patients. The study was performed in accordance with good clinical practice principles. Conflicts of Interest Don C. Rockey is the Co‐Editor‐in‐Chief of Portal Hypertension & Cirrhosis. He is therefore excluded from the peer‐review process and all editorial decisions related to the publication of this manuscript. The other author declares no conflicts of interest. Statement on the Use of Artificial Intelligence ChatGPT (OpenAI) assisted with conceptual design of the graphical abstract and generation of Python/R analytical and figure‐generation code. AI was NOT used for manuscript drafting, data interpretation or drawing study conclusions. All AI‐generated outputs were fully reviewed, corrected and verified by both authors. Supporting information Supporting File Acknowledgments This project was supported, in part, by the National Institutes of Health – the National Institute of Diabetes and Digestive and Kidney Disease (grant number P30 DK123704) and the National Institute of General Medical Sciences (grant number P20 GM130457), which supported Don C. Rockey. This study was also supported by Veterans Administration Medical Center, Yale School of Medicine (grant number Merit I01BX006016). Rao A. K., and Rockey D. C., “Recurrent and De Novo Cirrhosis After Liver Transplantation,” Portal Hypertension & Cirrhosis 5 (2026): 207‐213. 10.1002/poh2.70068. Managing Editor: Ting Liu Data Availability Statement The data that support the findings of this study were derived from the electronic health records of patients treated at MUSC. Due to institutional policies and the inclusion of protected health information, the data are not publicly available. De‐identified data may be made available from the corresponding author upon reasonable request and with appropriate institutional approval. References Associated Data Supplementary Materials Supporting File Data Availability Statement The data that support the findings of this study were derived from the electronic health records of patients treated at MUSC. Due to institutional policies and the inclusion of protected health information, the data are not publicly available. De‐identified data may be made available from the corresponding author upon reasonable request and with appropriate institutional approval.